T dosing of elranatamab in patients with relapsed or r mab in the majestec1 study of patients with relapsed/re tory multiple myeloma Total cost of care and cost per month of pfs were also assessed An estimated 14 (commercial) and 60 (medicare) rrmm patients per year would be eligible for treatment Adding elranatamab resulted in a total budget impact of $553,607 ($0.05 pmpm) in commercial and $2,351,515 ($0.20 pmpm) in medicare over three years. For patients who have relapsed following two to four prior treatments In august 2023, the u.s
Fda granted accelerated approval of elrexfio for the treatment of adult patients with relapsed or refractory multiple myeloma (rrmm) who have received at least four prior lines of therapy, including a.
OPEN
